Compare Sanofi SA (SNY) vs Invesco S&P 500 Momentum ETF (SPMO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Invesco S&P 500 Momentum ETF — how do they compare? Sanofi SA trades at $40.1 (market cap $96.81B), while Invesco S&P 500 Momentum ETF trades at $152 (market cap $23.47B). The key difference: Sanofi SA is far larger — about 4.1× Invesco S&P 500 Momentum ETF's market cap, and Sanofi SA pays a 6.02% dividend while Invesco S&P 500 Momentum ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sanofi SA for 94 Days and Invesco S&P 500 Momentum ETF for 54 Days on average.
| SNY | SPMO | |
|---|---|---|
Market Cap | $96.81B | $23.47B |
Volume | 2,081,815 | 2,035,258 |
Sector | Health | Broad Market / Factor |
52-Week High | $52.34 | $161.66 |
52-Week Low | $39.51 | $107.84 |
Typical Hold Time | 94 Days | 54 Days |
Enterprise Value | $116.20B | — |
Dividend Yield | 6.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $40.2, up 1.62% on the day, with a bearish technical signal from moving averages but a neutral oscillator stance. The company reported revenue of $46.72B in 2025 with a net income margin of 16.72%, and it has beaten EPS estimates for the last three quarters. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling strong pipeline development.
The outlook is mixed; analyst consensus leans hold (51.86%) with a buy rating at 44.44%, reflecting optimism on new drug launches but caution over future profit margin compression projected for 2026. Key risks include execution of the expanded Regeneron partnership and managing debt levels amid investing cash flow volatility.
SPMO trades at $153.00 with minimal daily movement (+0.01%). The ETF maintains a bullish technical stance with strong moving average signals, though oscillators show neutral momentum. Recent portfolio rebalancing added 54 stocks including Apple and Merck, while removing Nvidia. Institutional interest grew with Envestnet Asset Management increasing its stake by 9.5% in Q2 2026.
SPMO offers concentrated exposure to S&P 500 momentum leaders with historical outperformance. Key risks include sector concentration in technology and semiconductors, plus higher volatility than the broader market. The fund's momentum strategy faces challenges during market rotations but maintains structural advantages for long-term growth investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Invesco S&P 500 Momentum ETF
SPMO is designed to track the investment results of the S&P 500 Momentum Index. This index measures the performance of stocks in the S&P 500 that exhibit the highest momentum, or the greatest price appreciation, over the trailing 12 months, while excluding the most recent month. By investing in these high-momentum stocks, SPMO seeks to capitalize on the historical trend that stocks with strong recent performance tend to continue that performance in the near term, offering a systematic approach to factor investing within the large-cap U.S. equity market.
Read more on SPMO →
